They talk about us

Iktos and Astrogen announce a research collaboration to use artificial intelligence platform for drug design against a novel Parkinson’s disease target

Iktos announces collaboration with The University of Dundee, Drug Discovery Unit (DDU) to use AI for drug design and retrosynthesis

Iktos announces deployment of their AI for drug design software Makya by Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Iktos announces deployment of their AI drug design software Makya by Chiesi Group

Merck KGaA and Iktos announce a collaboration across three drug discovery projects

Servier and Iktos announce their successful collaboration in the field of artificial intelligence

Makya, Iktos’ SaaS platform

Iktos, one of the French health start-ups that matter

Iktos, winner of “Worldwide innovation Challenge Phase 2”

Le nouvel Economiste

Iktos, winner of Innov’up proto

News

Merck

Merck

January

2020

Merck buy a license of Makya

UCB

UCB

January

2020

Iktos initiate a research collaboration with UCB across three different projects. In September 2020, UCB buy a license of Spaya

Pfizer

Pfizer

August

2020

Pfizer buy a license of Kaya (Python version of Makya)

Alkermes

Alkermes

July

2020

Alkermes buy a license of Kaya (Python version of Makya)

Blueprint

Blueprint

June

2020

Iktos initiates a research
collaboration with Blueprint medicines

Lundbeck

Lundbeck

July

2020

Lundbeck buy a license of Kaya (Python version of Makya)

LEO Pharma

LEO Pharma

February

2020

Iktos initiates a research
collaboration with LEO Pharma

Awards

March

2018

Winner of the French

“Worldwide Innovation Challenge Phase 2”.

Iktos will benefit from non-dilutive funding from Bpifrance for 900k€

October

2017

Iktos wins the Innov’Up Proto challenge,

sponsored by the Paris region,

and will get a 100k€

non-dilutive funding.

March

2017

Iktos is labelled by
Cap Digital for
its application to
CMI and CIN challenges